Stage G3b, Category A2 and a Four Percent Five-Year Risk: Staging, Risk Prediction and a Referral Decision for Chronic Kidney Disease in a 70-Year-Old Woman With Hypertension
[Student Name]
University of Phoenix
NRP/556: Adult and Geriatric Management II
Week 2 Assignment
[Instructor Name]
[Date]
The patient is a composite written for a model paper.
Mrs. W., a 70-year-old retired postal clerk, has had hypertension for 20 years. Her last three estimated glomerular filtration rates over 18 months were 42, 40 and 38 mL/min/1.73 m², and her most recent spot urine showed albumin at 180 mg per gram of creatinine. She does not have diabetes. Her blood pressure averages 142/86 mm Hg on lisinopril 10 mg. She takes ibuprofen for arthritis most days. This paper explains how I staged her kidney disease and decided what to do.
Measuring Kidney Function Fairly
Estimated glomerular filtration rate is calculated from serum creatinine, age and sex. Older equations included a coefficient for Black race, which raised estimates for Black patients and could delay diagnosis and referral. Inker et al. (2021) developed and validated new equations without race using creatinine alone or creatinine and cystatin C, and found that the creatinine-cystatin C equation was most accurate. Our laboratory now reports the race-free creatinine equation. Mrs. W.'s values are consistent over 18 months, confirming chronic disease rather than an acute change.
Staging by Two Measures
KDIGO 2024 classifies chronic kidney disease by cause, GFR category and albuminuria category (Stevens et al., 2024). GFR categories range from G1, 90 or more, to G5, under 15; Mrs. W.'s 38 is G3b (30 to 44). Albuminuria categories are A1, under 30 mg/g; A2, 30 to 300; and A3, over 300. Her 180 mg/g is A2. Her stage is G3b A2, with hypertension as the probable cause.
Filtration tells me how much kidney is left; albumin tells me how fast it may be lost.
Why Both Measures Matter
The combination of GFR and albuminuria predicts the risks of kidney failure, cardiovascular events and death better than either alone. The KDIGO heat map colors each combination by risk; G3b A2 falls in a high-risk category (Stevens et al., 2024).
Predicting Kidney Failure
Tangri et al. (2011) developed and validated the Kidney Failure Risk Equation, which predicts progression to kidney failure using age, sex, estimated GFR and urine albumin-to-creatinine ratio, and found that it accurately predicted risk in independent cohorts. Using the four-variable equation, Mrs. W.'s five-year risk of kidney failure is about 4%. KDIGO 2024 recommends using a validated risk equation such as this to guide care and suggests referral to specialist kidney care when the five-year risk of kidney failure reaches roughly 3% to 5% (Stevens et al., 2024).
The Referral Decision
With a five-year risk of about 4% and albuminuria, Mrs. W. is at the threshold for nephrology referral. I refer her, noting that the nephrologist will help confirm the cause, optimize treatment and plan ahead. Our clinic keeps its role in her blood pressure, cholesterol and day-to-day care.
Slowing Progression: Blood Pressure and Albuminuria
Her blood pressure is above goal. KDIGO guidance favors a systolic target under 120 mm Hg when tolerated, measured with standardized technique, for adults with chronic kidney disease (Stevens et al., 2024). I increase lisinopril to 20 mg, since renin-angiotensin system inhibition reduces albuminuria and slows progression, and plan a repeat metabolic panel within about ten days; a small rise in creatinine, under 30%, is expected and acceptable.
Additional Kidney Protection
KDIGO 2024 recommends a sodium-glucose cotransporter-2 inhibitor for adults with chronic kidney disease and an estimated GFR of 20 or more with albuminuria of 200 mg/g or more, or with heart failure, irrespective of diabetes (Stevens et al., 2024). Mrs. W.'s albuminuria of 180 mg/g is just below that threshold; I will repeat the ratio and discuss this therapy with the nephrologist.
Stopping the Ibuprofen
By blunting the prostaglandins that keep blood flowing into the kidney, anti-inflammatory painkillers can hasten decline and cause acute kidney injury, especially with an ACE inhibitor. I recommend stopping daily ibuprofen and switching to acetaminophen and topical diclofenac for her arthritis.
Medication Review and Dosing
I review her medications for renal dosing and ask her to avoid over-the-counter drugs without checking. Her statin is continued, since chronic kidney disease raises cardiovascular risk.
What the Nephrologist Adds
Referral at this stage is not a sign that primary care has failed. A nephrologist can confirm that hypertension is the cause rather than another kidney disease, decide whether a kidney ultrasound or further testing is needed, optimize drugs that slow progression and, if decline continues, begin education about kidney replacement options years before they might be needed. Early referral is associated with better preparation when kidney failure does occur.
Complications to Watch
At stage G3b, complications of chronic kidney disease begin to appear: anemia, metabolic acidosis, disturbances of calcium, phosphate and parathyroid hormone and high potassium. Her blood count shows a mild anemia, and her bicarbonate sits at the low edge of normal. These will be tracked and treated if they worsen.
Cardiovascular Risk
People with chronic kidney disease are more likely to die of cardiovascular disease than to reach kidney failure. Mrs. W.'s statin, blood pressure control and avoidance of smoking protect her heart as much as her kidneys, and I make this point to her so that the plan does not feel like kidney care alone.
Explaining It to Mrs. W.
She asked whether she will need dialysis. I explained that her kidneys are working at a bit more than a third of normal, that her risk of needing dialysis in the next five years is about 4 in 100 and that the steps we are taking are meant to keep it that low or lower. Numbers helped her more than reassurance alone.
Vaccinations
People with chronic kidney disease are more vulnerable to infections. I review her vaccinations and recommend hepatitis B vaccination, which is advised for adults with chronic kidney disease who may later need dialysis, along with pneumococcal and annual influenza vaccines.
Diet
A referral to a dietitian will address sodium, which raises blood pressure and albuminuria, and protein intake, which should be moderate rather than restricted. Potassium intake does not need to be limited unless her potassium rises, which can happen as lisinopril is increased.
Why the Cause Matters
Hypertension is the likely cause, but other kidney diseases can cause albuminuria at her age. A urinalysis for blood and casts and a kidney ultrasound will help exclude glomerular disease or structural problems, and the nephrologist will decide whether further testing is needed.
Monitoring
Estimated GFR and albumin-to-creatinine ratio every six months at her stage, along with potassium, bicarbonate, hemoglobin and markers of bone and mineral health.
Conclusion
Mrs. W. has chronic kidney disease G3b A2 from hypertension, staged by both filtration and albuminuria under KDIGO 2024 using a race-free estimate of kidney function. The Kidney Failure Risk Equation puts her five-year risk near 4%, at the threshold for nephrology referral. Stronger blood pressure control with renin-angiotensin system inhibition, stopping ibuprofen and evaluating additional kidney protection aim to slow her progression.
References
Inker, L. A., Eneanya, N. D., Coresh, J., Tighiouart, H., Wang, D., Sang, Y., Crews, D. C., Doria, A., Estrella, M. M., Froissart, M., Grams, M. E., Greene, T., Grubb, A., Gudnason, V., Gutiérrez, O. M., Kalil, R., Karger, A. B., Mauer, M., Navis, G., . . . Levey, A. S. (2021). New creatinine- and cystatin C-based equations to estimate GFR without race. New England Journal of Medicine, 385(19), 1737-1749. https://doi.org/10.1056/NEJMoa2102953
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., Lamb, E., Lin, P., Madero, M., McIntyre, N., Morrow, K., Roberts, G., Sabanayagam, D., Schaeffner, E., Shlipak, M., . . . Levin, A. (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International, 105(4S), S117-S314. https://doi.org/10.1016/j.kint.2023.10.018
Tangri, N., Stevens, L. A., Griffith, J., Tighiouart, H., Djurdjev, O., Naimark, D., Levin, A., & Levey, A. S. (2011). A predictive model for progression of chronic kidney disease to kidney failure. JAMA, 305(15), 1553-1559. https://doi.org/10.1001/jama.2011.451
How this NRP 556 Week 2 example is structured
The NRP/556 Week 2 work usually addresses chronic kidney disease and urinary conditions. This paper moves through the staging and risk tools that define modern kidney care in primary practice, showing how each changes a decision. Students search this week as NRP 556 Week 2, NRP556 Wk 2 or NRP/556 Wk 2; all three are the same assignment.
NRP/556 Week 2 questions, answered
What does NRP/556 Week 2 usually ask for?
Many sections present a chronic kidney disease or urinary case and ask for staging, risk assessment, management and referral decisions.
How is chronic kidney disease staged?
By cause, GFR category (G1 to G5) and albuminuria category (A1 to A3), because both reduced filtration and albumin in the urine independently predict outcomes.
What is the Kidney Failure Risk Equation?
A validated model using age, sex, estimated GFR and urine albumin-to-creatinine ratio to predict the risk of kidney failure at two and five years, used to guide referral and planning.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official University of Phoenix document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.